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Outcomes in 12 gynecologic cancer patients with brain
metastasis: a single center’s experience
Esra ÇABUK CÖMERT1, Tevfik Berk BİLDACI1, Burcu KISA KARAKAYA1, Nefise Çağla TARHAN2,
Özlem ÖZEN3, Salih GÜLŞEN4, Polat DURSUN1, Ali AYHAN1

Aim: To present 12 gynecologic cancer cases with brain metastasis and a discussion of the relevant literature. Gynecologic
malignancy is the second most common cancer in elderly women, following breast cancer. These cancers usually spread
locally at first, and common distant metastatic sites are the lungs, liver, spleen, and distant lymph nodes. The brain is not
a usual site of metastatic involvement.
Materials and methods: The study included 12 cases with various gynecologic malignancies that were retrospectively
analyzed. Therapeutic modalities, survival, and time between initial surgery and brain metastasis were recorded.
Results: The mean survival was 41.4 months in 6 patients with ovarian cancer versus 27.7 months in those with other
gynecological cancers. At the time of brain metastasis, the CA-125 level was elevated in all of the patients, except one
that had cervical cancer. The mean CA-125 level was 202 IU mL–1. There were no differences in the mean overall
survival between the patients that underwent surgical resection and those that received medical treatment.
Conclusion: Brain metastasis can occur in all gynecologic cancers and has a poor prognosis, despite multimodal
treatment.
Key words: Gynecologic cancers, brain metastasis, ovarian carcinoma, cervical carcinoma, endometrial carcinoma

Kranial metastazı olan 12 jinekolojik onkoloji hastasının klinik gidişatı: Tek merkez deneyimi
Amaç: İleri yaş bayan hastalarda, jinekolojik malignensiler; meme kanserinden sonra en sık gözüken ikinci kanserlerdir.
Bu kanserler ilk olarak lokal yayılmaktadır ancak uzak metastazı akciğer, karaciğer, dalak ve lenf nodlarıdır. Beyin
olağan metastaz yeri değildir. Bu çalışmadaki amacımız jinekolojik kanserle takip edilen 12 hastanın beyin metastazını
literatür bilgisiyle beraber değerlerlendirmektir.
Yöntem ve gereç: Farklı jinekolojik kanser tanısı alan 12 hasta retrospektif olarak araştırıldı. Terapötik modaliteler,
yaşam süreleri, başlangıç cerrahisi zamanından; beyin metastazı olana kadar süredeki klinik gidişatları, CA-125
düzeyleri değerlendirildi.
Bulgular: Over kanseri ile takip edilen 6 hastanın ortalama yaşam süresi 41,4 aydı. Diğer jinekolojik kanserlerdeki
ortalama yaşam süresi ise 27,7 aydı. Servikal kanserler hariç CA-125 değeri beyin metastazı olduğu zaman yüksek
seyretmekteydi. CA-125: 202 IU mL–1 idi. Beyin metastazı olduktan sonra yapılan cerrahi girişim veya verilen medikal
tedavi arasında fark olmadığı saptanmıştır.
Sonuç: Beyin metastazı tüm jinekolojik onkoloji kanserlerinde gözükebilir ve de yapılan multimodal tedavi
yaklaşımlarına rağmen kötü prognoza sahiptir.
Anahtar sözcükler: Jinekolojik kanserler, beyin metastazı, over kanseri, servikal kanser, endometrial kanser
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Introduction

Results

Brain metastasis is common in patients with
leukemia, lymphoma, lung cancer, and breast cancer;
however, metastasis to the brain in patients with
gynecologic malignancies is uncommon, except in
choriocarcinoma (1,2). Epithelial ovarian carcinoma
(EOC), which is one of the most common gynecologic
malignancies, has clinical characteristics similar
to those of primary peritoneal carcinoma (PPC)
(3). Brain metastasis in EOC and PPC cases is rare,
usually present as a late manifestation in patients with
prolonged survival. The incidence of brain metastasis
in EOC ranges from 0.29% to 5% (4-7). Only 2 cases
of primary peritoneal adenocarcinoma metastasis
to the brain have been published (8,9). Endometrial
adenocarcinoma is the most common gynecologic
malignancy and has a low incidence of metastasis to
the brain, ranging from 0.3% to 1.4% (10,11).

Ovarian carcinoma

Metastatic disease to the central nervous system
(CNS) from other gynecological malignancies, such as
cervical cancer, uterine sarcomas, and vulvar cancer, is
extremely rare. For example, only a few reports of brain
metastasis in vulvar carcinoma patients have been
published in the English-language literature (12,13).
Herein, we report the radiological findings, treatment
modalities, outcomes, and survival of 12 gynecological
cancer patients with metastasis to the brain that
were treated between 2007 and 2010 at the Başkent
University Department of Gynecologic Oncology.
Materials and methods
This retrospective study included gynecological
cancer patients with metastasis to the brain that were
treated at Başkent University between January 2007
and January 2010. The retrospective design of the
study eliminated the necessity of ethical committee
approval. Pathologic classification of the cancers,
treatment regimens, time from onset of disease to
detection of brain metastasis, extracranial metastasis
and time of occurrence, changes in the CA-125 level,
and overall survival (OS) are provided, along with
brain imaging findings. Additionally, survival and
factors involved in prognosis are discussed. SPSS
17 was used for statistical analysis. Dichotomous
variables were analyzed using the chi-square test and
numeric variables were analyzed using the t-test. P <
0.05 was considered statistically significant.
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Among 435 patients with EOC, 6 (1.4%) (mean
age: 60 years; range: 45-74 years) developed brain
metastasis. In all, 5 of these 6 patients had serous
adenocarcinoma and 1 had clear cell adenocarcinoma.
All 6 patients underwent cytoreductive surgery,
performed by an experienced gynecologic oncology
team. All 5 patients with serous adenocarcinoma
had stage IV cancer, and they received paclitaxel and
carboplatin as first-line chemotherapy. Only 1 of the
serous adenocarcinoma patients achieved remission
without recurrence during the 12 months of followup; the 5 other patients had disease-free survival
(DFS) of 6 months. Other chemotherapeutic agents,
including liposomal doxorubicin, gemcitabine,
topotecan, weekly paclitaxel, and oral tamoxifen,
were used one by one in the mentioned order until
recurrence occurred or an increase in CA-125 was
observed.
The mean Ca-125 level was 249 IU mL–1 (range:
2-735 IU mL–1) at the time that CNS metastasis was
noted. The mean survival after cytoreduction in the
stage IV cancer patients was 41.9 months (range: 2779 months); following brain metastasis, the mean
survival was limited to 2.92 months (range: 0-6
months), regardless of the therapy used. Three patients
that underwent surgical resection due to cranial
metastasis had OS of 3.3 months following surgery.
The other 3 patients opted for medical treatment and
had OS of 2.2 months. Among the 3 patients that
were surgically treated, 1 had cranial recurrence and
again underwent surgery. The difference between
treatment regimens was not significant (P = 0.605).
Results in the patients with stage III cancer were
similar; OS was 39 and 2 months following diagnosis
and surgical resection, respectively (Table).
Other gynecologic malignancies
In all, 247 patients with endometrial cancer underwent
various surgical and medical treatments during
the study period, and 2 developed brain metastasis
(0.8%); histopathological types were endometrioid
and serous papillary adenocarcinoma. Both patients
underwent initial staging and cytoreductive surgery.
The patient with serous papillary cancer was stage
IB, grade 3, and the patient with an endometrioid
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Table. Features of patients with gynecologic cancers that metastasized to brain.
Type of
gynecological
malignancies

Number of sites
involved in CNS

Operation status

Radiotherapy
status for brain
metastasis

Interval between initial and
second diagnosis / Survival
after brain metastasis

Patient A: Ovarian
serous carcinoma

2 sites

NA

NA

34 m / 4 m

Patient B: Ovarian
serous carcinoma

1 site

Operated

RT

26 m / 9 m (alive)

Patient C: Ovarian
serous carcinoma

2 sites

Operated

RT

72 m / 6 m

Patient D: Ovarian
serous carcinoma

2 sites

Operated

RT

28 m / 4 m

Patient E: Ovarian
serous carcinoma

1 site

NA

NA

36 m / 7 d

Patient F: Ovarian
clear cell carcinoma

4 sites

NA

NA

35 m / 2 m

Malignant mixed
müllerian tumor

2 sites

NA

NA

5m/2m

Endometrial carcinoma
(endometrioid)

2 sites

Only biopsy

RT

29 m / 30 m (alive)

Endometrial
carcinoma (serous)

1 site

NA

NA

2m/5m

Primary
peritoneal carcinoma

3 sites

NA

NA

13 m / 2 m

Cervical
carcinoma

1 site

Operated

RT

4m/1m

Vulvar
carcinoma

4 sites

NA

NA

36 m / 12 d

*NA: not applicable, RT: radiotherapy, m: months, d: days

tumor was stage IIIA, grade 3. Both patients received
6 cycles of paclitaxel and carboplatin (175 mg m–2
dose for paclitaxel and AUC 5 dose for carboplatin)
following cytoreduction. Metastatic disease to the
brain occurred with synchronous disseminated
abdominal spread in both patients. Elevated CA-125
was observed in these 2 patients (163 IU mL–1) at the
time that CNS involvement was noted.
During the study period, we treated 10 malignant
mixed müllerian tumor (MMMT) patients; 1 patient
had stage 4 disease and developed brain metastasis
4 months after initiation of cisplatin and liposomal
doxorubicin. Imaging methods, including abdominal
and thoracic tomography, showed concomitant lung
metastasis and disseminated abdominal spread.
Survival following brain metastasis was only 3
months (Table).

Of the 172 patients with cervical carcinoma
treated during the study period, 1 developed
cranial metastasis; the patient underwent type-3
hysterectomy and bilateral pelvic and paraaortic
lymph node dissection following 28 days of
chemoradiation with 6 cycles of platin-based
chemotherapy. Histopathological evaluation showed
both pelvic and paraaortic lymph nodes consistent
with clear cell adenocarcinoma. DFS was 24 months
prior to the occurrence of brain metastasis, after
which time the patient survived for 1 month (Table).
Of the 28 patients with PPC, 1 had brain
metastasis during the study period. The treatment
administered to this patient was similar to that
given to EOC patients; following cytoreductive
surgery, chemotherapy consisting of paclitaxel and
carboplatin was administered. DFS was 6 months
387
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prior to recurrence. Although the time between
the initiation of the therapy and brain metastasis
was 13 months, survival after brain metastasis was
1.5 months. Among the 37 patients with vulvar
carcinoma, 1 had brain metastasis (squamous cell
adenocarcinoma). The patient first underwent surgery
at another hospital in 2006, but following recurrence
in 2007, vulvectomy and bilateral inguinal lymph
node dissection were performed at our hospital.
This patient was stage III (FIGO). She received
5000 cGy of pelvic radiotherapy concomitant with
3 cycles of cisplatin and doxorubicin. DFS before
brain metastasis was 2.3 months; survival after brain
metastasis was less than 1 month.

Clinical imaging
The brain metastases observed in the present study
were associated with such clinical manifestations
as
headache,
nausea,
vomiting,
tinnitus,
unconsciousness, dizziness, loss of extremity
movement, and ptosis. In most of the patients,
metastatic disease was diagnosed via magnetic
resonance imaging (MRI). Figures 1 and 2 show
different brain metastasis sites of the patients. Figures
3 shows hystopathologic images of brain metastasis
from different patients. Figures 1 and 2 clearly
show that the location of metastatic spread varied
(temporal, parietal, frontal lobe, and cerebellum).

i) Right parietal lobe involvement on ii) Right parietal lobe involvement on
transverse section of patient A.
coronal section of patient A.

iii) Cerebellar involvement on
coronal section of patient B.

iv) Cerebellar infiltration on
transverse section of patient C.

vi) Left temporoparietal lobe
involvement of patient D.

v) Occipital lobe involvement on
transverse section of patient C.

Figure 1. Metastasis at different sites with different (coronal and transverse) sections from ovarian cancer patients.
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i)Left lateral ventricule involvement
on transverse section MMMT.

ii)Right occipito parietal lobe
involvement on transverse section,
cervical cancer.

iv)Right frontal, left parietal lobe
involvement on transverse section,
primary peritoneal cancer.

v)Cerebellar involvement on
coronal section, endometrial
cancer.

iii)Cerebellar involvement on
coronal section, vulvar
carcinoma .

Figure 2. Imaging of brain metastasis in other gynecologic malignancies.

While single intracranial metastasis occurred in
3 patients, multiple intracranial metastases occurred
in 9 patients. In 2 patients with ovarian cancer, 1 with
cervical cancer, and 1 with endometrial cancer, there
was no recurrence other than brain involvement
based on abdominal and thoracic screening. The
other patients had multiple abdominal metastases. In
all, 1 patient with single metastasis and 4 with multiple
intracranial metastases underwent intracranial
focus resection followed by radiotherapy. Among
the 5 patients that received radiation treatment,
only 1 also received chemotherapy. There were no
differences in the mean OS between the patients with
brain metastases that underwent surgical resection,

medical therapy, and radiotherapy (P = 0.859), which
was 2.2 months for all of the 12 patients. The patient
with endometrial cancer and multiple intracranial
metastases underwent stereotaxic biopsy following
gamma-knife radiotherapy and was still alive 19
months after treatment. In total, 4 patients with
multiple intracranial metastases and 3 with single
intracranial metastasis were given palliative therapy.
Discussion
The incidence of brain metastasis in clinical series of
gynecological cancers is approximately 1% (14,15). In
the present study, 6 of 435 patients with EOC developed
389
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4× magnification

4× magnification

10× magnification

10× magnification

Figure 3. Histopathologic images of brain metastasis from different types of patients with different magnification values.

brain metastasis (1.3%). The mean age of patients
with EOC and brain metastasis varied from 50.4 to
59.3 years (range: 19-77 years) in different studies,
and 3% of these patients were stage III and IV (16).
In the present study, 6 patients with EOC had serous
adenocarcinoma, the most frequently encountered
type, which is similar to previous findings (16). The
mean age of these 6 patients was 60 years (range: 4574 year); all but 1 had advanced-stage disease (stage
III and IV), 5 had serous adenocarcinoma, and 1 had
clear cell adenocarcinoma.
The current standard treatment for EOC of
all histological subtypes involves primary optimal
debulking surgery followed by cisplatin-based
chemotherapy. It is well known that almost all
390

patients with EOC receive chemotherapy after initial
diagnosis. Some researchers have suggested that the
increased incidence of brain metastasis in EOC is
related to the effectiveness of chemotherapy (15) or
that cisplatin-based chemotherapy may contribute
to an increase in the incidence of CNS involvement
(4,14,17). The blood-brain barrier (BBB) is thought
to limit delivery of large-in-size hydrophilic drugs to
the brain, determining which agents and doses will
be used (14). Additionally, some researchers think
that improvement in the efficacy of chemotherapy
delays reoccurrence in the abdominal and pelvic
cavity, but that the BBB blocks water-soluble cisplatin
and lowers the concentration in the CNS, increasing
the incidence of brain metastasis (18).
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Brain metastasis usually occurs in patients with
longer survivals. The maximum time from diagnosis
of EOC to brain metastasis was 98 months, and the
longest survival period after brain metastasis was 7
years (19,20). Tay and Rajesh reported that median
survival after brain metastasis was 19.5 months,
whereas Chen et al. reported that the mean time from
initial diagnosis of EOC to brain metastasis was 24.3
months and median survival after the discovery of
CNS involvement was 3 months (21,22). In the present
study, the mean survival after cytoreduction in stage
III-IV cancer patients was 41.9 months (range: 2779 months), and after brain metastasis was detected,
mean survival was limited to 2.92 months (range: 0-6
months), regardless of treatment. Tay et al. suggested
that monitoring tumor recurrence based on the
serum CA-125 level does not predict metastasis to
the brain, as only 1 of 4 cases had elevated CA-125 at
the time brain metastasis was diagnosed (21). All of
the EOC patients with brain metastasis in the present
study had elevated CA-125 (mean: 249 IU mL–1;
range: 44-735 IU mL–1), as might occur in cases of
recurrence in other regions of the body.
The prognosis of patients with brain metastasis
is generally very poor without adjuvant treatment,
ranging from none to a few months of survival (2023). The aim of treatment in patients with brain
metastasis should be the control of neurological
symptoms and improvement of the quality of life.
There are various treatment strategies, including
corticosteroids, whole-brain radiotherapy (WBRT),
surgery, radiosurgery, and chemotherapy. WBRT
is the treatment of choice for most patients with
brain metastasis of various malignancies; however,
it can cause acute toxicity, such as skin irritation,
alopecia, and otitis media. Single metastasis occurs
in 43% of patients with EOC; approximately 50% of
these patients are not surgical candidates because
of extracranial disease or tumor inaccessibility
(24). Treating single brain metastasis with surgical
resection (with or without WBRT) improves OS
(25). Patchell et al. reported that cases of solitary
brain metastasis of any histological type treated with
surgical excision plus WBRT had longer DFS, longer
OS, and longer duration of functional independence
compared to those treated with WBRT alone
(26). In patients with limited intracranial tumors,
focal therapeutic modalities such as gamma-knife

radiosurgery (GKS) may replace WBRT or surgery,
which delivers high-dose focal radiation and induces
tumor necrosis while delivering minimal radiation to
the surrounding normal brain tissue (23,25). In all,
3 patients in the present study underwent surgical
resection following WBRT. Patients that were not
treated for metastatic disease because of their medical
condition had 2 months of OS, whereas those that
underwent surgical resection and radiotherapy had 5
months of OS, and 1 patient was still alive 8 months
after the detection of CNS involvement.
Other types of gynecologic malignancies
Few case reports and studies describe patients with
endometrial carcinoma and brain metastasis (11).
The incidence of brain metastasis from endometrial
carcinoma ranges from 0.3% to 1.4% (10,11). The
primary mechanism of spread was suggested to be
dissemination to the lungs and to the brain via the
pulmonary vasculature (27,28). Many studies report
that brain metastasis in endometrial cancer is usually
associated with widespread disease, as in 2 patients
in the present study (29,30). Advanced stage, high
grade, invasion of the lymphovascular space, and
deep myometrial invasion are associated with brain
metastasis (10,27,30,31). Tumor grade and deep
myometrial invasion were correlated in the present
study. The mean interval between diagnosis of
primary tumor and CNS involvement ranges from 0
to 52 months (10,28,32,33). These results seem to be
compatible with our study, as 15.5 months was our
time interval for CNS involvement to be found. In
the present study, the mean OS after the diagnosis
of brain metastasis was 17.5 months (1 patient was
still alive when this report was written). In contrast,
2 patients treated with surgical resection following
radiotherapy had long-term OS (82 and 83 months)
after the development of brain metastasis (10,33).
In the present study, 1 of the patients was still alive
(at the time this report was written) 30 months
after stereotaxic biopsy following GKS. Chura et al.
(34) reported that survival in patients treated with
multimodal therapy (WBRT plus surgery, WBRT
plus chemotherapy, or WBRT plus surgery and
chemotherapy) was longer than in patients treated
with WBRT only (P = 0.0001) and in patients that
received no treatment (P = 0.009); no difference in
OS was observed between the patients treated with
391
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WBRT only and those not treated. Other studies
also support the survival advantage associated with
multimodal therapy (10,32).
Brain metastasis from a MMMT of the uterus is
very rare. To date, 4 cases of CNS involvement with
MMMT metastasis have been reported (35,36).
The pathological stage at diagnosis seems to be the
most reliable predictor of prognosis in MMMTs of
uterine origin (36). Surgical excision is considered
the most effective treatment, whereas radiotherapy
and various combinations of chemotherapy have
achieved inconsistent results. However, Wong
et al. observed that patients with MMMT of the
uterus that received sequential adjuvant therapy,
namely cisplatin and ifosfamide chemotherapy and
radiotherapy, had longer survival compared with the
control group without any adjuvant therapy (37). The
4 cases mentioned above had mean survival times
of 2 months after the detection of brain metastasis;
complete tumor resection or cranial radiotherapy
alone did not provide a good prognosis (35,36,38).
Even though surgical resection or other mentioned
therapies were not an option for the patient with
MMMT in the present study because of her poor
medical condition, OS after CNS involvement was 2
months. Based on the limited data in the literature, it
is thought that a poor prognosis in MMMT patients
with brain metastasis is unavoidable.
Brain metastasis from cervical cancer occurs in
0.4%-1.2% of patients (39,40). The mean OS after
initial diagnosis of cervical cancer was 19.2 months and
the mean survival after diagnosis of brain metastasis
ranged from 3 to 8 months (39-41). The treatment of
brain metastasis usually involves radiation therapy,
surgery, or both, depending on each patient’s clinical
picture. Generally, surgical excision is used in cases
with a solitary lesion or adjacent multiple metastases.
Patients with nonadjacent, multiple, or inoperable
lesions are usually treated with palliative WBRT

(39,41). In the present study’s patient, the time
from initial diagnosis to multiple metastatic CNS
involvement was 4 months; nevertheless, survival was
only 1 month after the discovery of brain metastasis.
Though WBRT was planned, due to the patient’s
poor medical condition she was given paclitaxel and
carboplatin combination chemotherapy.
Brain metastasis from EOC and PPC is considered
a rare occurrence. In a series of 24 patients (23 with
EOC and 1 with PPC), Ratner et al. reported that
OS was 37 months (42). In the present study, there
was a significant difference in survival between EOC
and PPC patients; OS in the EOC patients was 41.9
months versus 15 months in the PPC patients. On the
other hand, there was a small difference in survival
after brain metastasis between the EOC and PPC
patients (2.92 and 2 months, respectively), which was
also reported by Ratner et al. (42). Surgical resection
of cranial mass was not performed due to the patient’s
medical condition. As in EOC, survival following
brain metastasis in PPC is limited.
Distant spread occurs in 8%-12% of patients with
vulvar carcinomas. To date, brain metastasis from
vulvar carcinoma has been reported in only 4 cases
with different histopathological features. Our patient
had squamous cell carcinoma and DFS of 36 months
from initial diagnosis to secondary brain metastasis;
following brain metastasis, the patient survived for
12 days.
Although gynecologic cancers rarely metastasize
to the brain, brain metastasis in such cases has a poor
prognosis despite combined treatment modalities.
Radiation therapy and surgery are effective in only
partially removing masses. Unfortunately, on the basis
of the known facts and our experience, chemotherapy,
especially paclitaxel and carboplatin, functions only
as palliation in such patients. Additional research on
other chemotherapy regimens and targeted therapies
in such patients with brain metastasis is warranted.
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